EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma
- 24 September 2003
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 107 (4) , 673-675
- https://doi.org/10.1002/ijc.11448
Abstract
CMM is the most serious cutaneous malignancy and is increasing in frequency among most Caucasian populations, where the most important risk factor is exposure to UV light. Relatively little is known of the genetic factors that mediate susceptibility to and prognosis in sporadic CMM, although a number of genes have been implicated. A striking association between EGF polymorphism and Breslow thickness of invasive CMM has been reported. We have sought confirmation of this finding in an independent study of 159 patients and 310 controls using TaqMan fluorescence‐based genotyping for EGF +61. In our study group, there were no significant differences in EGF genotype frequencies between patients and controls nor was EGF genotype associated with tumour growth phase, stage or mitotic count. However, correlation between EGF genotype and Breslow thickness showed a modestly significant increase in frequency of the EGF (G/G) genotype among tumours >3.5 mm thick (30.0% vs. 9.8%, p = 0.03). In summary, in our group, the EGF +61 polymorphism was not a risk factor for CMM susceptibility, but this polymorphism may play a role in disease progression.Keywords
This publication has 15 references indexed in Scilit:
- Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanomaGenes & Immunity, 2002
- Association between functional polymorphism in EGF gene and malignant melanomaThe Lancet, 2002
- Melanocortin 1 Receptor (MC1R) Gene Variants are Associated with an Increased Risk for Cutaneous Melanoma Which is Largely Independent of Skin Type and Hair ColorJournal of Investigative Dermatology, 2001
- IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanomaGenes & Immunity, 2001
- Cytochrome P450 CYP2D6 genotypesPharmacogenetics, 1999
- HLA‐DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian populationTissue Antigens, 1998
- The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanomaHuman Molecular Genetics, 1996
- HLA‐DQB1*0301 association with increased cutaneous melanoma riskInternational Journal of Cancer, 1994
- Cutaneous malignant melanoma, Scotland, 1979-89The Lancet, 1992
- A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Research, 1988